To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium
Nuffield Department of Population Health, Big Data Institute, University of Oxford, Oxford, UK.
Örebro University, School of Medical Sciences. Örebro University Hospital. National Reference Laboratory for Neisseria meningitidis, Department of Laboratory Medicine, Clinical Microbiology.
Örebro University Hospital. Örebro University, School of Medical Sciences. National Reference Laboratory for Neisseria meningitidis, Department of Laboratory Medicine, Clinical Microbiology.
Nuffield Department of Population Health, Big Data Institute, University of Oxford, Oxford, UK.
Number of Authors: 992023 (English)In: The Lancet Digital Health, E-ISSN 2589-7500, Vol. 5, no 9, p. e582-e593Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The Invasive Respiratory Infection Surveillance (IRIS) Consortium was established to assess the impact of the COVID-19 pandemic on invasive diseases caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and Streptococcus agalactiae. We aimed to analyse the incidence and distribution of these diseases during the first 2 years of the COVID-19 pandemic compared to the 2 years preceding the pandemic.

METHODS: For this prospective analysis, laboratories in 30 countries and territories representing five continents submitted surveillance data from Jan 1, 2018, to Jan 2, 2022, to private projects within databases in PubMLST. The impact of COVID-19 containment measures on the overall number of cases was analysed, and changes in disease distributions by patient age and serotype or group were examined. Interrupted time-series analyses were done to quantify the impact of pandemic response measures and their relaxation on disease rates, and autoregressive integrated moving average models were used to estimate effect sizes and forecast counterfactual trends by hemisphere.

FINDINGS: Overall, 116 841 cases were analysed: 76 481 in 2018-19, before the pandemic, and 40 360 in 2020-21, during the pandemic. During the pandemic there was a significant reduction in the risk of disease caused by S pneumoniae (risk ratio 0·47; 95% CI 0·40-0·55), H influenzae (0·51; 0·40-0·66) and N meningitidis (0·26; 0·21-0·31), while no significant changes were observed for S agalactiae (1·02; 0·75-1·40), which is not transmitted via the respiratory route. No major changes in the distribution of cases were observed when stratified by patient age or serotype or group. An estimated 36 289 (95% prediction interval 17 145-55 434) cases of invasive bacterial disease were averted during the first 2 years of the pandemic among IRIS-participating countries and territories.

INTERPRETATION: COVID-19 containment measures were associated with a sustained decrease in the incidence of invasive disease caused by S pneumoniae, H influenzae, and N meningitidis during the first 2 years of the pandemic, but cases began to increase in some countries towards the end of 2021 as pandemic restrictions were lifted. These IRIS data provide a better understanding of microbial transmission, will inform vaccine development and implementation, and can contribute to health-care service planning and provision of policies.

FUNDING: Wellcome Trust, NIHR Oxford Biomedical Research Centre, Spanish Ministry of Science and Innovation, Korea Disease Control and Prevention Agency, Torsten Söderberg Foundation, Stockholm County Council, Swedish Research Council, German Federal Ministry of Health, Robert Koch Institute, Pfizer, Merck, and the Greek National Public Health Organization.

Place, publisher, year, edition, pages
Elsevier, 2023. Vol. 5, no 9, p. e582-e593
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-107485DOI: 10.1016/S2589-7500(23)00108-5ISI: 001074027700001PubMedID: 37516557Scopus ID: 2-s2.0-85168804100OAI: oai:DiVA.org:oru-107485DiVA, id: diva2:1786796
Funder
Wellcome trustTorsten Söderbergs stiftelseStockholm County CouncilSwedish Research CouncilPfizer AB
Note

Funding agencies:

National Institutes of Health Research (NIHR)  

Spanish Government  

Korea Disease Control and Prevention Agency

German Federal Ministry of Health 

Robert Koch Institute

Merck & Company  

Greek National Public Health Organization

Available from: 2023-08-10 Created: 2023-08-10 Last updated: 2023-10-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Jacobsson, SusanneMölling, Paula

Search in DiVA

By author/editor
Jacobsson, SusanneMölling, Paula
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
The Lancet Digital Health
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 17 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf